US CMS Nominee Verma Advances To Senate Floor On Narrow Vote
Executive Summary
Seema Verma, President Trump's nominee to lead the Medicare agency, was approved by the Senate Finance Committee March 2 on a narrow 13-12 vote; her confirmation will now be taken up by the full Senate. Questions remain about Verma's viewpoints related to replacement of the Affordable Care Act and on promoting alternative Medicare value-based payment models.
You may also be interested in...
Senate Committee Signals Approval Of Seema Verma To Run CMS, But Most Dems Will Vote 'No'
At a Senate Finance Committee markup on the confirmation of Seema Verma to become CMS administrator, a majority of senators signaled approval of Verma, but most Democrats said they will vote "no" in response to their dissatisfaction with her written answers on issues, including past conflicts-of-interest, ACA repeal and Medicaid changes. A binding committee vote is expected March 2.
Leap In US Sales Of IUDs Linked To Trump Election, ACA Repeal Efforts
Sales of contraceptive intrauterine devices rose in the 4th quarter of 2016 at some companies. The increase in interest in IUDs coincides with efforts to repeal Obamacare and eliminate contraceptive coverage guarantees, according to Planned Parenthood and AthenaHealth.
CMS Nominee Seema Verma Urges Caution On Competitive Bidding Program
Seema Verma, President Trump’s pick to run the US Medicare agency, told the Senate Finance Committee that rural areas should not have to comply with CMS’ medical supplies competitive-bidding program if it is not a good fit. Verma was also questioned on changes she might make to the Affordable Care Act and the Medicare program, but did not offer many specifics.